Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. | Chris ...

Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the must-buy penny stocks to invest in now. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is accelerating its drug development programs and unlocking ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to invest in now. On April 30, TheFly reported that JPMorgan trimmed the price target on Recursion ...

Good morning, tech fam; here are some quick tech updates for you to catch on to! What’s New Today: AI chip startup Cerebras ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.